Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Available Frontline Treatment Options for Patients With Advanced or Recurrent Endometrial Cancer

September 22nd 2023

Krishnansu Tewari, MD, details the first-line treatment options for patients with recurrent endometrial cancer.

FDA Grants Priority Review to Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer

September 20th 2023

The FDA has granted priority review to a supplemental biologics license application seeking the approval of pembrolizumab in combination with external beam radiotherapy plus concurrent chemotherapy, followed by brachytherapy, for the treatment of newly diagnosed patients with high-risk, locally advanced cervical cancer.

Patient Profile Presentation: A 64-Year-Old Woman With Recurrent Endometrial Cancer

September 15th 2023

Ramez Eskander, MD, presents the profile of a 64-year-old postmenopausal woman diagnosed with recurrent endometrial carcinoma for discussion.

Overview of Endometrial Carcinoma

September 15th 2023

Ramez Eskander, MD, and Krishnansu Tewari, MD, provide an overview of endometrial cancer, including prevalence, staging criteria, and molecular profiling.

FDA Grants Fast Track Status to Tulmimetostat for Endometrial Cancer

September 13th 2023

The FDA has granted fast track designation to tulmimetostat for use as a potential therapeutic option in patients with advanced, recurrent, or metastatic endometrial cancer harboring ARID1A mutations and whose disease had progressed on at least 1 prior line of therapy.

Dr Birrer on Molecular Stratification in Endometrial Cancer

September 8th 2023

Michael J. Birrer, MD, PhD, discusses the benefits of molecular profiling in patients with endometrial cancer, the variety of mutations that have been identified in this disease, and how stratifying patients based on the biomarkers their disease harbors allows for more individualized treatment decisions.

Dr Pothuri on the Promise of the RUBY and NRG-GY018 Trials in Endometrial Cancer

September 7th 2023

Bhavana Pothuri, MD, discusses the promise of the phase 3 NRG-GY018 and RUBY trials in patients with endometrial cancer.

Tisotumab Vedotin Improves OS in Recurrent/Metastatic Cervical Cancer

September 5th 2023

Treatment with tisotumab vedotin-tftv monotherapy led to an improvement in overall survival compared with chemotherapy alone in patients with recurrent or metastatic cervical cancer that progressed on or after frontline therapy.

Prolgolimab Combo Shows Antitumor Activity and Safety in Advanced Cervical Cancer

September 1st 2023

Administration of the anti–PD-1 antibody prolgolimab in combination with bevacizumab and platinum-doublet chemotherapy resulted in high response rates and a favorable safety profile in patients with recurrent or metastatic cervical cancer.

Dr Santin on the Investigation of Sacituzumab Govitecan in Endometrial Cancer

August 30th 2023

Alessandro Santin, MD, discusses the investigation of sacituzumab govitecan in patients with recurrent endometrial carcinoma overexpressing TROP2.

Geptanolimab Elicits Durable Responses and Acceptable Safety in PD-L1+ Cervical Cancer

August 29th 2023

The novel anti-PD-1 antibody geptanolimab demonstrated durable antitumor activity and favorable tolerability in patients with recurrent or metastatic PD-L1–positive cervical cancer who previously progressed on a platinum-based regimen.

FDA Approval Insights: Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced Endometrial Cancer

August 28th 2023

Dr Mirza discusses the FDA approval of dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer; key efficacy and safety findings from the RUBY trial, and ongoing research investigating the role of frontline immune checkpoint inhibitors in patients with endometrial cancer.

Dr Pothuri on the Phase 3 NRG-GY018 and RUBY Trials in Endometrial Cancer

August 25th 2023

Bhavana Pothuri, MD, discusses the phase 3 NRG-GY018 and RUBY trials in patients with endometrial cancer.

TROP2 Expression Predicts Sacituzumab Govitecan Activity in Recurrent Endometrial Cancer

August 24th 2023

Alessandro Santin, MD, discusses the rationale and design of a phase 2 trial of sacituzumab govitecan in patients with persistent or recurrent endometrial cancer; unmet needs for patients with this disease; and key findings from the stage 1 portion of the trial.

Dr Hitchins on Investigating Constitutional MLH1 Methylation in CRC and Endometrial Cancers

August 22nd 2023

Megan Hitchins, PhD, discusses the rationale for conducting an analysis on the prevalence of high-risk constitutional MLH1 methylation in patients with early-onset colorectal cancer and endometrial cancer.

Dr Hitchins on the Association Between Constitutional MLH1 Methylation and MRD in Select Cancers

August 15th 2023

Megan Hitchins, PhD, discusses results from an analysis on the prevalence of high-risk constitutional MLH1 methylation in early-onset colorectal and endometrial cancers displaying mismatch repair deficiency.

BAT8006 Elicits Disease Control, Safety in Advanced Ovarian Cancer and Other Solid Tumors

August 14th 2023

Treatment with the folate receptor–α antibody-drug conjugate BAT8006 led to responses with a manageable safety profile in patients with advanced solid tumors, including ovarian cancer, breast cancer, and cervical cancer.

BDC-1001 Monotherapy Under Further Evaluation in Phase 2 Trial in HER2+ Cancers

August 11th 2023

The first patients have been dosed in the phase 2 portion of a phase 1/2 trial evaluating BDC-1001 monotherapy in patients with HER2-positive colorectal cancer, endometrial cancer, and gastroesophageal cancer.

Future Outlook for Treatment of Endometrial Cancer

August 10th 2023

The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.

Ongoing Trials in Endometrial Cancer

August 10th 2023

An overview of ongoing research in the endometrial cancer treatment space.